drugset / Trial / NCT00616070

Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601-003)

NCT00616070

Phase 3 Completed 120 enrolled Sirion Therapeutics, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this phase III study is to determine the safety and efficacy of difluprednate in the management of inflammation following ocular surgery.

Timeline

Start
2007-12
Primary completion
2008-03
Completion
2008-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Difluprednate Small molecule

Indications

No indication recorded.